Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 03/05/2024 am IST After market 01:48:18 am
125.6 USD +12.68% Intraday chart for Moderna, Inc. 126.4 +0.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Softer Late Afternoon MT
Equity Markets Higher Ahead of Apple Earnings MT
S&P 500, Nasdaq Rise Intraday Amid Moderna Rally as Traders Await Apple Results MT
Sector Update: Health Care Stocks Retreat Thursday Afternoon MT
RBC Raises Price Target on Moderna to $135 From $125 MT
Sector Update: Health Care MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple... Our Logo
News Highlights : Top Company News of the Day - Thursday at 11 AM ET DJ
Moderna Maintains Full-Year Sales Guidance Following First-Quarter Beat MT
News Highlights : Top Company News of the Day - Thursday at 9 AM ET DJ
Powell did it again Our Logo
Chardan Research Lowers Metagenomi's PT to $17 From $21 on Heels of Announced Termination of Collaboration With Moderna, Keeps Buy Rating MT
Transcript : Moderna, Inc., Q1 2024 Earnings Call, May 02, 2024
Moderna Q1 Swings to Loss, Revenue Plummets; 2024 Outlook Affirmed MT
News Highlights : Top Company News of the Day - Thursday at 7 AM ET DJ
Moderna: sales plummet in Q1 CF
Stock Futures Gain Pre-Bell as Fed Leaves Key Rate Unchanged; Asia, Europe Churn MT
Earnings Flash (MRNA) MODERNA Posts Q1 Revenue $167M MT
Moderna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Moderna quarterly sales beat expectations but plummet from previous year RE
Futures climb as Fed allays rate-hike worries RE
Moderna's Top-Line Sales Seen to Start Growing in 2025, Oppenheimer Says MT
Wall Street: buoyed by Tesla, confident ahead of FOMC meeting CF
Wall Street: buoyed by Tesla, confident ahead of FOMC meeting CF
Moderna Signs Nonexclusive License Deal in Japan for COVID-19-related Intellectual Property MT
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
111.5 USD
Average target price
134.3 USD
Spread / Average Target
+20.49%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Moderna : COVID-19 Vaccine Gets Approval For Emergency Use in Japan